Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter (Q2) of Fiscal Year 2008, ended September 30, 2007.
Business Overview: A vertically integrated global pharmaceutical company manufacturing Active Pharmaceutical Ingredients (API) and Finished Dosage forms, with a focus on the US, Europe, India, and Russia.
Key Financial Metrics
| Metric | Q2 FY08 (Actual) | Q2 FY07 (Prior Year) |
|---|---|---|
| Revenue | Rs 12,670 million ($319 million) | Rs 20,000 million ($504 million) |
| Profit Before Tax (PBT) | Rs 1,422 million ($36 million) | Rs 3,531 million ($89 million) |
| Profit After Tax (PAT) | Rs 2,672 million ($67 million) | Rs 2,798 million ($70 million) |
| Exchange Rate Used | 1 USD = Rs 39.75 | N/A |
Note: The filing text does not provide specific data on cash flow, debt levels, or liquidity ratios for this period.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 37% year-over-year. This decline is primarily attributed to the absence of Rs 7.8 billion ($196 million) in upside from authorized generics recorded in Q2 FY07.
- Organic Growth: Excluding the authorized generics impact from the prior year, revenue grew by 4% in rupee terms and 20% in dollar terms.
- Profitability: PBT decreased significantly from Rs 3,531 million to Rs 1,422 million. However, PAT remained relatively stable (Rs 2,672 million vs. Rs 2,798 million) due to a one-time benefit.
- One-Time Benefit: A reversal of deferred tax liability related to the Betapharm acquisition resulted in a benefit of Rs 1.5 billion ($36.5 million) in Q2 FY08.
Segment Performance and Management Commentary
- India (Finished Dosage): Revenue increased 9% to Rs 2 billion, driven by key brands and new product launches.
- Russia (Finished Dosage): Revenue increased 25% to Rs 980 million, driven by key brands and new launches.
- North America (Finished Dosage): Revenue increased 63% to Rs 2 billion (excluding prior year authorized generics). Combined revenues from fexofenadine and finasteride were Rs 1.2 billion.
- Germany (Betapharm): Revenue declined to Rs 1.9 billion from Rs 2.6 billion due to supply constraints and rupee appreciation against the Euro. However, pharmacy volumes grew 28% in July and August 2007.
- API Business: Revenue increased 11.5% to Rs 3.2 billion.
- Custom Pharmaceutical Services: Organic segment revenue surged 125% to Rs 528 million.
Outlook/Contingencies: The company is on track to transfer key products out of Salutas by the end of FY08. No specific forward guidance or risk factors were detailed in this specific filing text beyond the operational updates.
Investor Verification Checklist
- Verify the impact of the Rs 1.5 billion deferred tax reversal on the reported Net Income to understand core operating profitability.
- Confirm the status of supply constraints in the German (Betapharm) operations and their resolution timeline.
- Assess the sustainability of the 63% growth in North American finished dosages excluding the one-time authorized generic benefit from the prior year.
- Review the full annual report (Form 20-F) for detailed cash flow, debt, and liquidity metrics not included in this press release summary.